Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intraocular hemocoagulase in human vitrectomy

S H Kim1, Y S Cho, Y J Choi

  • 1Department of Ophthalmology, Kyungpook National University Hospital, Taegu, Korea.

Japanese Journal of Ophthalmology
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular physiology, biochemistry, and pharmacology of Alzheimer's amyloid precursor protein (APP).

Annals of the New York Academy of Sciences·1996
Same author

Preventive effect of enalapril on erythrocytosis after renal transplantation.

Transplantation proceedings·1996
Same author

Novel pre-C/C gene mutants of hepatitis B virus in chronic active hepatitis: naturally occurring escape mutants.

The Journal of general virology·1996
Same author

CT and MR findings of Krukenberg tumors: comparison with primary ovarian tumors.

Journal of computer assisted tomography·1996
Same author

Case Report. CT and US features of renal matrix stones with calcified center.

Journal of computer assisted tomography·1996
Same author

Left subclavian artery bypass graft in complicated arterial switch operation.

The Annals of thoracic surgery·1996

Intravitreal hemocoagulase significantly reduced bleeding time during vitrectomy surgery. This agent also demonstrated safety, with no observed ocular toxicity or adverse effects on visual acuity.

Area of Science:

  • Ophthalmology
  • Surgical Innovation
  • Hemostasis

Background:

  • Vitrectomy is a common surgical procedure for various retinal conditions.
  • Bleeding during vitrectomy can complicate the surgery and affect outcomes.
  • Hemocoagulase is a hemostatic agent with potential applications in ophthalmic surgery.

Purpose of the Study:

  • To evaluate the efficacy of intravitreal hemocoagulase in reducing bleeding time during vitrectomy.
  • To assess the ocular toxicity and safety profile of intravitreal hemocoagulase.
  • To determine the impact of hemocoagulase on hemostasis in the postoperative period.

Main Methods:

  • A prospective study involving 60 patients undergoing vitrectomy for diabetic retinopathy, ocular injury, or retinal vascular disorders.

Related Experiment Videos

  • Patients were assigned to receive either hemocoagulase in BSS Plus or BSS Plus alone.
  • Bleeding time was measured after cutting proliferative attachments; ocular toxicity and electroretinography were assessed postoperatively.

    • Main Results:

    • Intravitreal hemocoagulase significantly reduced intraoperative bleeding time, facilitating surgical procedures.
    • Hemocoagulase assisted in maintaining hemostasis during the first week after diabetic vitrectomy.
    • No disadvantage was observed in postoperative electroretinography, and no adverse effects on the cornea, lens, or visual acuity were noted.

    Conclusions:

    • Intravitreal hemocoagulase is effective in reducing bleeding during vitrectomy, thereby improving surgical efficiency.
    • The use of hemocoagulase in the vitreous cavity appears safe and well-tolerated, with no significant ocular toxicity.
    • Hemocoagulase shows promise as an adjunct for hemostasis in complex vitreoretinal surgeries.